Anixa Biosciences (ANIX) CEO Amit Kumar Buys $52K of Stock
Amit Kumar, CEO of ANIX, purchased 21,000 shares on June 12, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Amit Kumar, Chief Executive Officer at Anixa Biosciences, Inc. ($ANIX), bought 21,000 shares at an average price of $2.50, worth about $52,500, on June 12, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $ANIX is up 12.2% after 1 week, up 23.9% after 1 month and up 8.1% to date (from the $2.47 close on Jun 12, 2026).
Key Points
- ANIX CEO Amit Kumar bought 21,000 shares at $2.50 each on June 12, 2026, totaling $52,500.
- ANIX shares currently trade around $2.48, with recent insider buying activity from both Kumar and other executives.
- Analysts from D. Boral Capital and HC Wainwright & Co. maintain 'buy' ratings on ANIX, with price targets up to $10.
Get $ANIX trade alerts by text
We text you when insiders, Congress or big funds trade $ANIX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Anixa Biosciences, Inc. alert may contain errors. Disclosures
Amit Kumar, the CEO of ANIX, recently bought 21,000 shares of the company on June 12, 2026. He purchased the shares at an average price of $2.50 each, amounting to a total transaction value of $52,500. This purchase was not part of a pre-arranged trading plan.
Insider Buying and Selling at Anixa Biosciences, Inc.
Kumar's recent purchase adds to previous insider activity at ANIX. Earlier in the year, on January 5, 2026, Kumar acquired 350,000 shares. Other insiders, including Arnold Baskies and Emily Gottschalk, also made purchases on the same date. Baskies bought an additional 10,000 shares on January 28, 2026, at $3.04 per share.
Other Institutional Activity in ANIX
Several institutional investors have also been active in ANIX. Vanguard Capital Management LLC acquired 1,314,982 shares, now holding shares valued at approximately $3.39 million. Laird Norton Wetherby Trust Company, LLC reduced its position by 21,700 shares, ending with 566,327 shares worth about $1.46 million. UBS Group AG increased its holdings by 92,564 shares, bringing its total to 551,637 shares valued at roughly $1.42 million. Meanwhile, D.A. Davidson & Co. maintained its holdings at 539,272 shares, valued at approximately $1.39 million.
Anixa Biosciences, Inc. Stock Down 10.5%
ANIX shares are currently trading around $2.48. Despite recent insider buying, the stock remains volatile, attracting attention from both institutional investors and analysts. The company's financial metrics and market conditions continue to be closely monitored by stakeholders.
Analysts Set New Price Targets
Analysts have maintained a positive outlook on ANIX. On March 31, 2026, D. Boral Capital maintained its 'buy' rating with a price target of $10. Similarly, HC Wainwright & Co. reiterated its 'buy' rating with a $7 target on September 11, 2025. The consensus among analysts is a 'buy' rating, with a mean target price reflecting optimism about the company's future performance.
About ANIX
ANIX is a company engaged in developing innovative solutions across various sectors. With a focus on cutting-edge research and development, ANIX aims to deliver high-quality products and services to its customers. The company is led by CEO Amit Kumar and operates from its headquarters, striving to make significant contributions to its industry.
Bottom Line
Amit Kumar's recent purchase of ANIX shares underscores his confidence in the company's prospects. While insider buying is often seen as a positive signal, it's important to remember that these transactions do not guarantee future stock performance. Investors and analysts will continue to keep a close eye on ANIX's developments and market conditions.
Source: Amit Kumar's Form 4 filing on $ANIX (Jun 12, 2026). Find the original filing: ANIX Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts
